Research programme: attention deficit hyperactivity disorder therapies - SoseiAlternative Names: Bifemelane hydrochloride; SON-216
Latest Information Update: 27 Feb 2008
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Sosei
- Class Benzhydryl compounds
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder
Most Recent Events
- 02 Jun 2005 Preclinical trials in Attention-deficit hyperactivity disorder in USA (unspecified route)